Regeneron CEO Says its Covid Antibody Treatment Protects for up to 8 Months
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) says that within its late-stage trial, a single dose of its antibody cocktail decreased the risk of contracting Covid-19 by 81.6%. The company’s shares rose 12% following the news. The data is anticipated to back the regulatory review intended to prolong therapy’s use in preventing Covid-19 in patients that are …
Regeneron CEO Says its Covid Antibody Treatment Protects for up to 8 Months Read More »